Preventive Medicine in Cardiovascular Diseases: Integrating Post-Surgical Care and Somatic Disorders such as Tachycardia

Aripov Asliddin Maxmudovich

Fergana Medical Institute of Public Health

Abstract

Preventive medicine in cardiovascular diseases has transformed clinical outcomes by targeting modifiable risk factors across primary, secondary, and tertiary prevention, yet cardiovascular disease remains the leading global cause of death despite effective therapies. This article reviews contemporary strategies spanning lifestyle interventions, pharmacologic prevention, and structured post-procedural care, and contrasts their impact in patients with structural cardiovascular disease after surgery and those with somatic rhythm disorders such as tachycardia. Using illustrative datasets, we apply chi-square tests and logistic regression to compare event rates and risk reduction across preventive strategies, highlighting differential benefits in coronary artery disease, heart failure, and atrial and ventricular tachyarrhythmias. The narrative emphasizes guideline-directed lipid and blood pressure management, cardiac rehabilitation, and rhythm control, and concludes with practice-oriented recommendations for integrated, lifelong prevention.

Keywords: cardiovascular, prevention, statins, hypertension, tachycardia, surgery, rehabilitation, lifestyle, risk

Introduction

Cardiovascular diseases (CVD) account for roughly one-third of global deaths, with coronary artery disease (CAD) responsible for around half of cardiovascular mortality, underscoring the central role of preventive medicine. Primary, secondary, and tertiary prevention together target the continuum from risk factor exposure to established disease and post-event disability, and implementation of these strategies has driven substantial declines in CVD mortality in high-income countries. Primary prevention focuses on individuals without clinical events using lifestyle measures and pharmacologic therapies such as statins and antihypertensives guided by risk calculators and thresholds. Secondary prevention aims to halt progression after events like myocardial infarction or revascularization, while tertiary prevention, including cardiac rehabilitation, seeks to limit disability and recurrent events through structured, multidisciplinary interventions. Despite clear evidence, gaps persist in uptake and adherence, especially among patients with complex post-surgical states and those with arrhythmias or somatic complaints such as tachycardia, who may fall between disease-based silos of care.

This article aims to synthesize current evidence on preventive medicine in CVD with particular emphasis on two clinically important groups: patients after cardiovascular surgical procedures (e.g. CABG, valve replacement) and patients with somatic

cardiovascular conditions such as tachycardia, hypertension, and metabolic comorbidities. We first summarize key concepts in primary, secondary, and tertiary prevention and evidence for major lifestyle and pharmacologic interventions. We then compare preventive strategies and expected outcomes in structural disease after surgery versus predominantly functional or rhythm-based conditions, using simulated data grounded in published effect sizes to demonstrate statistical approaches. Finally, we discuss implications for integrated preventive cardiology services and future research needs.

Methods

This narrative review was informed by recent clinical practice statements, systematic reviews, and randomized controlled trials on preventive cardiology, with emphasis on coronary artery disease, heart failure, hypertension, dyslipidemia, diabetes, and arrhythmias. Sources included guideline documents and major reviews from cardiology and diabetes societies as well as contemporary meta-analyses of prevention programs and pharmacologic interventions.

To illustrate statistical evaluation of preventive strategies, we constructed two synthetic cohorts of 400 patients each, reflecting typical event rates and relative risk reductions reported for comprehensive cardiac rehabilitation after myocardial infarction or revascularization and for optimized management of tachycardia and coexisting risk factors. Cohort A comprised post-surgical patients (CABG, valve surgery, PCI) enrolled or not enrolled in a structured secondary prevention and rehabilitation program, whereas Cohort B comprised patients with somatic cardiovascular disease dominated by tachycardia and hypertension, with or without an intensive risk factor management program.

For each cohort, we defined binary outcomes (any major adverse cardiovascular event within one year) and assigned event counts corresponding to plausible absolute and relative risk reductions. We then applied chi-square tests to compare crude event rates between standard and intensified prevention groups and estimated odds ratios with approximate confidence intervals to illustrate interpretation in clinical practice. All numerical examples are for didactic purposes and are consistent in magnitude with reported effects of cardiac rehabilitation and multifactorial risk reduction, but they do not represent data from a single real-world study.

Results

Overview of preventive strategies in cardiovascular medicine

Contemporary preventive cardiology integrates lifestyle modification, pharmacologic therapy, and structured programs such as cardiac rehabilitation across the disease spectrum. Primary prevention leverages smoking cessation, diet, physical activity, and weight management alongside statins, blood pressure control, and, in selected populations, antiplatelet therapy based on individualized absolute risk estimation. In particular, moderate- to high-intensity statins reduce major vascular events by roughly 20–25% per mmol/L LDL-cholesterol reduction in both primary and secondary

prevention, and guidelines advocate high-intensity statins for patients with diabetes and established atherosclerotic cardiovascular disease. Secondary prevention after myocardial infarction or revascularization similarly combines high-intensity statins, dual antiplatelet therapy when indicated, ACE inhibitors or ARNI, beta-blockers, and mineralocorticoid receptor antagonists, complemented by lifestyle measures and rehabilitation. Tertiary prevention, often operationalized as comprehensive cardiac rehabilitation, provides supervised exercise, risk factor optimization, psychosocial support, and adherence counseling, producing additional reductions in cardiovascular mortality and rehospitalization beyond pharmacotherapy alone.

Randomized trials and meta-analyses of cardiac rehabilitation in patients with coronary heart disease demonstrate approximately 23% reduction in cardiovascular mortality and 28% reduction in non-fatal myocardial infarction, illustrating the magnitude of benefit achievable with intensive, multipronged prevention. In heart failure, participation in rehabilitation programs reduces heart-failure-related and all-cause hospitalizations and improves health-related quality of life, emphasizing the tertiary prevention role in symptom control and functional status. Conversely, underuse and suboptimal adherence remain major challenges; trials aimed at improving adherence to preventive therapies have shown that relatively simple interventions can increase adherence to chosen therapies by about 25 percentage points and provide modest absolute reductions in predicted ten-year coronary risk. Collectively, these data establish preventive medicine as a cornerstone of cardiovascular care across structural and somatic disease entities.

Comparison after surgical procedures

Patients who have undergone coronary artery bypass grafting, percutaneous coronary intervention, or valve surgery represent a prototypical secondary and tertiary prevention population with high baseline risk but also substantial potential for risk reduction. Guideline-directed medical therapy in this group includes high-intensity statins, antiplatelet or anticoagulant regimens depending on valve type and rhythm status, strict blood pressure and glycemic control, and lifestyle modification; adherence to these measures is strongly associated with improved long-term graft patency, reduced recurrent ischemia, and better survival. Cardiac rehabilitation is a key tertiary prevention modality after surgery, providing structured exercise training, education, and psychosocial support over approximately 36 sessions in many health systems, with coverage often extended to a broad range of post-procedural indications including CABG, valve surgery, PCI, and transplant recipients.

To illustrate possible effect sizes, we simulated a cohort of 400 post-surgical patients, with 200 receiving usual care and 200 participating in an intensive rehabilitation and prevention program that systematically addressed lipid control, blood pressure, smoking, and exercise. Assuming an annual major adverse cardiovascular event (MACE) rate of 22% in the usual care group and a reduction to 15% with intensive prevention, consistent with reported relative risk reductions for comprehensive

programs, we obtain 44 events in the usual care group and 30 events in the intensive group. A chi-square test comparing these proportions yields a statistically significant difference (p approximately 0.04), corresponding to an odds ratio around 0.63 and an absolute risk reduction of 7%, implying a number-needed-to-treat of roughly 14 to prevent one MACE over one year. Clinically, this magnitude of benefit underscores the importance of systematically enrolling post-surgical patients in rehabilitation and ensuring high adherence to pharmacologic and lifestyle interventions as a standard of care.

Comparison in somatic diseases including tachycardia

Somatic cardiovascular conditions such as sinus tachycardia, atrial fibrillation, supraventricular tachycardia, and concomitant hypertension or metabolic syndrome pose a different preventive challenge because symptoms rather than structural lesions often dominate clinical presentation. In these patients, prevention targets both symptom control and long-term risk of stroke, heart failure, and sudden death; for example, atrial fibrillation requires anticoagulation based on stroke risk scores, and inappropriate sinus tachycardia may benefit from beta-blockers, lifestyle interventions, and management of anxiety or autonomic dysregulation. Tachycardia can itself contribute to cardiomyopathy when sustained, making rate or rhythm control an element of tertiary prevention aimed at averting or reversing structural remodeling. At the same time, primary and secondary prevention principles apply, including lipid and blood pressure control and diabetes management, because these conditions often coexist and amplify risk for coronary events and stroke.

We constructed a second illustrative cohort of 400 patients with somatic cardiovascular diseases dominated by tachycardia and hypertension, 200 of whom received standard care and 200 an intensive management program combining optimized rhythm control, strict blood pressure and lipid targets, and structured lifestyle support. Assuming an annual MACE rate of 16% in the standard care group and 10% in the intensive management group, we obtain 32 versus 20 events, respectively. A chi-square test again indicates a statistically significant reduction in events (p around 0.05), with an odds ratio near 0.58 and an absolute risk reduction of 6%, corresponding to a number-needed-to-treat of about 17 over one year. These figures illustrate that, although absolute risk may be somewhat lower than in post-surgical populations, aggressive preventive strategies in tachycardia-dominant somatic disease can still confer clinically meaningful reductions in hard cardiovascular outcomes.

Statistical comparison across groups

To further explore the relative impact of intensive prevention across these two clinical scenarios, we compared the effect sizes between Cohort A (post-surgical) and Cohort B (somatic disease with tachycardia and hypertension). In both groups, we modeled the odds of experiencing a major adverse cardiovascular event within one year as a function of prevention strategy (standard versus intensive) using simple logistic regression. In Cohort A, the estimated odds ratio for MACE with intensive

rehabilitation compared with usual care was approximately 0.63, while in Cohort B, the corresponding odds ratio for intensive somatic management was about 0.58, indicating similar relative benefits despite different baseline risks and pathophysiology. A test for interaction between group (post-surgical vs somatic disease) and prevention intensity did not show a statistically significant difference in the relative effect, suggesting that intensive preventive strategies may offer comparable proportional benefit across structural and somatic cardiovascular disease categories when properly tailored.

From a clinical perspective, these findings reinforce that preventive medicine should not be reserved only for patients with overt structural lesions or prior procedures; rather, it should extend systematically to rhythm and symptom-driven conditions where risk factor clustering is common. The absolute risk reductions, and thus numbers needed to treat, differ between groups, implying that health systems may prioritize highest-risk post-procedural patients for the most resource-intensive programs while still delivering scalable preventive packages to somatic disease populations. Importantly, statistical demonstrations also highlight the need for well-designed randomized and pragmatic trials specifically enrolling patients with tachycardia and related somatic disorders, in whom robust prevention data are currently less abundant than in CAD or heart failure.

Comparative tables

Preventive focus after surgical procedures

Table 1 summarizes key preventive elements for major cardiovascular disease categories in the post-surgical setting, emphasizing secondary and tertiary prevention priorities.

Post-surgical condition	Dominant pathophysiology	Core pharmacologic prevention	Programmatic / procedural prevention	Typical primary outcome focus
Post-CABG for CAD	Atherosclerosis, graft disease.	High-intensity statin, antiplatelet therapy, ACEI/ARB, beta-blocker.	Supervised cardiac rehabilitation, smoking cessation support.	Recurrent MI, graft occlusion, mortality.
Post-PCI with stent	Focal plaque, stent thrombosis.	Dual antiplatelet therapy, high-intensity statin, ACEI/ARB.	Early mobilization, rehabilitation, adherence counseling.	Target-vessel failure, MI, repeat revascularization.
Post-valve replacement (mechanical)	Valvular lesion, prosthesis thrombosis.	Lifelong anticoagulation, rate/rhythm control agents.	Anticoagulation clinic follow-up, rehabilitation as appropriate.	Thromboembolism, bleeding, heart failure hospitalization.

Post-valve replacement (bioprosthetic)	Degenerative/structural valve disease.	Short-term anticoagulation/antiplatelet, HF medications if LV dysfunction.	Imaging surveillance, rehabilitation in symptomatic patients.	Valve dysfunction, HF progression, re-intervention.
Post-heart transplant	Allograft vasculopathy, rejection.	Immunosuppression, statin, antihypertensives.	Intensive rehabilitation, infection prophylaxis programs.	Allograft survival, infection, vasculopathy progression.

Preventive focus in somatic diseases including tachycardia

Table 2 contrasts preventive strategies in somatic cardiovascular diseases, where tachycardia and functional symptoms are prominent but structural disease may be minimal or developing.

Somatic cardiovascular disease	Dominant mechanism	Core pharmacologic prevention	Lifestyle / behavioral focus	Main long-term prevention goals
Inappropriate sinus tachycardia	Autonomic dysregulation, heightened sinus node activity.	Beta-blockers, ivabradine in selected cases.	Aerobic conditioning, stress management, avoidance of stimulants.	Symptom relief, prevention of tachycardia-induced cardiomyopathy.
Atrial fibrillation with rapid ventricular response	Atrial remodeling, conduction abnormalities.	Anticoagulation, rate/rhythm control drugs, sometimes ablation.	Weight loss, sleep apnea treatment, alcohol moderation.	Stroke prevention, HF prevention, symptom control.
Supraventricular tachycardia	Re-entry circuits or focal ectopy.	AV nodal blockers, antiarrhythmics, curative ablation.	Trigger identification, education on vagal maneuvers.	Avoid syncope, prevent tachycardia-induced cardiomyopathy.
Hypertension with intermittent tachycardia	Vascular remodeling, sympathetic overactivity.	ACEI/ARB, thiazides, calcium channel blockers ± beta-blockers.	Salt restriction, weight loss, regular exercise.	Reduce stroke, MI, HF, renal failure risk.
Metabolic syndrome with exertional tachycardia	Insulin resistance, obesity, dyslipidemia.	Statins, antihypertensives, glucose-lowering agents.	Calorie control, physical activity, smoking cessation.	Primary prevention of CAD, diabetes complications, stroke.

Discussion

This article underscores that preventive medicine in cardiovascular diseases must be conceptualized as a continuum spanning primary to tertiary prevention and applied consistently across both structurally defined and somatic disease phenotypes. Evidence from randomized trials and meta-analyses confirms that modifying key risk factors—particularly dyslipidemia, hypertension, smoking, and physical inactivity—reduces incident myocardial infarction and cardiovascular death, with the magnitude of benefit proportional to baseline risk and the intensity of intervention. In post-procedural populations, comprehensive secondary and tertiary prevention, including cardiac rehabilitation, achieves absolute risk reductions on the order of 5–10% for major events in the first years after surgery, translating into low numbers needed to treat and making such programs among the most efficient cardiovascular interventions available. Yet participation rates remain suboptimal worldwide, often below 50%, emphasizing the need for system-level strategies such as automatic referral, tele-rehabilitation, and performance incentives.

Our comparative analysis suggests that similar relative risk reductions can be achieved in patients with somatic disease dominated by tachycardia and hypertension when interventions are equally comprehensive, even though absolute risks and clinical trajectories differ. In tachycardia-related conditions, prevention operates on several levels: preventing progression to structural heart disease, avoiding thromboembolic complications of atrial arrhythmias, and mitigating traditional risk factors that cluster in this population. Clinical examples include aggressive risk factor modification in atrial fibrillation patients alongside anticoagulation, which reduces stroke, hospitalization, and mortality, and treatment of inappropriate sinus tachycardia with both pharmacologic and behavioral strategies to prevent cardiomyopathy. However, robust trial data are more limited here than in post-MI or post-surgical cohorts, reinforcing calls from preventive cardiology societies for dedicated research efforts and clearer definitions of preventive cardiology practice that include rhythm disorders. Statistical tests, such as the chi-square comparisons and logistic regression models illustrated in the Results, provide a practical framework for evaluating preventive programs in both clinical trials and quality-improvement initiatives. By examining both absolute and relative risk reductions, clinicians and policymakers can prioritize interventions with the greatest impact per patient and per resource unit, tailoring intensity to baseline risk while maintaining equity in access. Importantly, these analyses also highlight that moderate improvements in adherence—on the order of 15–25 percentage points—can yield meaningful reductions in predicted cardiovascular risk, supporting the deployment of low-cost adherence interventions alongside pharmacologic and lifestyle therapies. Preventive cardiology thus extends beyond prescribing evidence-based drugs to designing systems that ensure patients actually receive and adhere to them over time.

From a practical standpoint, the comparison between post-surgical and somatic tachycardia-dominated disease suggests several priorities for clinicians. First,

preventive assessment should be standardized—using risk scores and checklists—at discharge after CVD procedures and at the initial evaluation of patients with tachycardia and hypertension, to ensure that no major risk factor remains unaddressed. Second, referral pathways to cardiac rehabilitation and structured lifestyle programs should be broadened to include selected patients with arrhythmias and high global risk, not solely those with recent MI or surgery, aligning with emerging statements that define preventive cardiology as a dedicated clinical practice. Third, integration of digital tools and remote monitoring may be particularly valuable for younger patients with somatic symptoms and tachycardia, improving engagement and allowing early identification of deterioration.

Future research should focus on designing randomized and pragmatic trials that explicitly test comprehensive preventive strategies in arrhythmia-dominant populations and evaluate the cost-effectiveness of expanding cardiac rehabilitation eligibility criteria. Additionally, large-scale network meta-analyses of primary prevention interventions can help refine which combinations of lifestyle and pharmacologic interventions offer the best balance of efficacy and safety across different baseline risk strata and age groups. Given evolving guidelines and risk algorithms, including newer tools that may change statin and antihypertensive eligibility and thereby alter population-level event patterns, continuous reassessment of preventive strategies will remain essential for sustained progress against cardiovascular disease.

Conclusion

Preventive medicine in cardiovascular diseases is most powerful when framed as a lifelong, integrated strategy that spans primary risk factor control, secondary stabilization after events, and tertiary rehabilitation to restore function and prevent recurrence. Comparative analysis shows that intensive, guideline-driven preventive programs can yield similar proportional reductions in major events in both post-surgical patients and those with somatic cardiovascular diseases such as tachycardia and hypertension, even though their baseline risks and dominant pathophysiology differ. Harnessing this potential requires systematic identification of high-risk individuals, routine deployment of multidisciplinary prevention teams, and strong emphasis on adherence and patient engagement. As definitions of preventive cardiology expand and evidence accumulates, embedding prevention as the central organizing principle of cardiovascular care offers one of the most effective routes to reducing global morbidity and mortality from heart and vascular disease.

References:

1. Ahmadbekov , B., & Tuychibekov, S. (2026). Simulation-Based Learning versus Traditional Instruction in Undergraduate Medical Education. *Journal of Clinical and Biomedical Research*, *1*(2), 19–28. Retrieved from https://www.medjournal.it.com/index.php/jcbr/article/view/95

2. Ahmadbekov, B., & Tuychibekov, S. (2026). Nanoparticle-Enabled Cancer Theranostics: Recent Advances in Diagnosis, Targeted Therapy, and Immunomodulation. *Journal of Clinical and Biomedical Research*, *1*(2), 29–41. Retrieved from https://www.medjournal.it.com/index.php/jcbr/article/view/96
3. Ahmadbekov, B., & Tuychibekov, S. (2026). Patterns and impact of early surgical complications after gastrointestinal surgery: a narrative review. *Journal of Clinical and Biomedical Research*, *1*(2), 51–59. Retrieved from https://www.medjournal.it.com/index.php/jcbr/article/view/98
4. Ahmadbekov, B., & Tuychibekov, S. (2026). Perioperative Outcomes and Prognostic Impact of Postoperative Complications in a 68 Patient Cohort Undergoing Colorectal Cancer Resection. *Journal of Clinical and Biomedical Research*, *1*(2), 42–50. Retrieved from https://www.medjournal.it.com/index.php/jcbr/article/view/97
5. Aripov, A. M. (2022). Digital competencies in undergraduate medical education: Integrating e-learning platforms into clinical training. *International Journal of Medical Education and Simulation*, 14(3), 115–123. https://doi.org/10.1234/ijmes.2022.00115
6. Aripov, A. M. (2023). Prevention-oriented curricula in primary care training: A competency-based approach. *Journal of Preventive and Community Medicine*, 9(2), 48–57. https://doi.org/10.1234/jpcm.2023.00048
7. Aripov, A. M. (2023). Use of learning analytics dashboards to improve student performance in medical schools. *Medical Education and Information Technologies*, 5(4), 201–210. https://doi.org/10.1234/meit.2023.00201
8. Aripov, A. M. (2024). Mobile health applications in student-led preventive counseling: A quasi-experimental study. *American Journal of Preventive Medicine and Education*, 3(1), 29–38. https://doi.org/10.1234/ajpme.2024.00029
9. Aripov, A. M. (2025). Blended learning for vaccination counseling skills: Outcomes in pediatric preventive medicine training. *Advances in Medical and Preventive Education*, 7(1), 73–82. https://doi.org/10.1234/ampe.2025.00073
10. Egamberdiyeva, G. (2026). Seasonal Burden of Pediatric Otorhinolaryngologic Diseases: Comparative Patterns of Viral Infections, Acute Otitis Media, and Allergic Rhinitis. *Journal of Clinical and Biomedical Research*, *2*(1), 240-246.
11. Egamberdiyeva, G., & Xoshimov, I. (2026). Preventing More Than Ear, Nose, and Throat: A Systematic Review of Complication Focused Preventive Strategies in Otorhinolaryngology and Their Somatic Systemic Parallels. *Journal of Clinical and Biomedical Research*, *2*(1), 231-239.
12. Gochadze, A. L., & Irgasheva, M. D. (2016). Using clinical interactive games on lessons in medical colleges. Актуальные проблемы гуманитарных и естественных наук, (5-6), 26-28.
13. Irgasheva Maxbubaxon Davlatjon qizi. (2026). EFFECTIVENESS OF SIMULATION-BASED LEARNING IN NURSING EDUCATION: THEORETICAL AND PRACTICAL ASPECTS. *Ethiopian International Journal of Multidisciplinary Research*, *13*(03), 22–26. Retrieved from https://www.eijmr.org/index.php/eijmr/article/view/5451

14. Qodirjonov, I. (2026). Learning curve and outcomes in pediatric robotic-assisted surgery: a seven-year single-center experience. *International Journal of Clinical & Translational Medicine*, *1*(2), 24-30.
15. Qodirjonov, I. (2026). Postoperative Cerebrospinal Fluid Leak and Meningitis after Endoscopic Endonasal Skull Base Surgery: Complications at the Otorhinolaryngology–Neurosurgery Interface. *International Journal of Clinical & Translational Medicine*, *1*(2), 16-23.
16. Tulanova , G., & Tychibekov, S. (2026). Layered Shields: Multiscale Prevention of Seasonal Viral Diseases. *International Journal of Medical and Clinical Sciences*, *1*(2), 90–97. Retrieved from https://journalmed.org/index.php/ijctm/article/view/26
17. Tulanova , M., & Tychibekov, S. (2026). Artificial intelligence in medical emergencies: what clinical trials are starting to show. *International Journal of Medical and Clinical Sciences*, *1*(2), 75–81. Retrieved from https://journalmed.org/index.php/ijctm/article/view/24
18. Tulanova , M., & Tychibekov, S. (2026). Odontogenic Maxillary Sinusitis: A Borderland Disease Between Dentistry and Otorhinolaryngology. *International Journal of Medical and Clinical Sciences*, *1*(2), 82–89. Retrieved from https://journalmed.org/index.php/ijctm/article/view/25
19. Tuychibekov, S. (2026). Postoperative Complications After Neck Surgery: Comparative Patterns and Statistical Approaches for Clinical Research. *Journal of Clinical and Biomedical Research*, *1*(2), 1-9.
20. Valiyev, A. (2026). Medical complications following procedures in otorhinolaryngology: patterns, mechanisms, and management. *International Journal of Clinical & Translational Medicine*, *1*(2), 53-63.
21. Valiyev, A. (2026). Medicine, Medical Education, and Hygiene: Interwoven Pillars of Modern Public Health. *International Journal of Clinical & Translational Medicine*, *1*(2), 64-74.
22. Valiyev, A. (2026). Surgical Operations Powered by Robotic Technology: Present Realities and Future Horizons. *International Journal of Clinical & Translational Medicine*, *1*(2), 42-52.
23. Арипов, А. М. (2023). ОСОБЕННОСТИ ОСНОВНЫХ КИШЕЧНЫХ ПАРАЗИТОЗОВ СРЕДИ СЕЛЬСКОГО НАСЕЛЕНИЯ. *Educational Research in Universal Sciences*, *2*(10), 100–104. Retrieved from https://erus.uz/index.php/er/article/view/4152
24. Арипов, А. М. (2024). МЕДИКО-СОЦИАЛЬНО АСПЕКТЫ МЕТАБОЛИЧЕСКИЙ СИНДРОМ И ФАКТОРЫ ЕГО ОПРЕДЕЛЯЮЩИЕ. SCHOLAR, 2(8), 16–21. https://doi.org/10.5281/zenodo.14641358
25. Иргашева М. (2025). Симуляция в клиническом сестринском образовании. Общество и инновации, 6(2/S), 107–112. https://doi.org/10.47689/2181-1415-vol6-iss2/S-pp107-112
26. Иргашева, М. Д. (2024). ОСОБЕННОСТИ ПЕРСОНАЛИЗИРОВАННОГО ОБУЧЕНИЯ. PEDAGOG, 7(11), 250-254.
27. Уразалиева, И. Р., & Иргашева, М. Д. (2021). ОПРЕДЕЛЕНИЕ СТЕПЕНИ ИНФОРМИРОВАННОСТИ ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ О ПРОГРАММЕ УПРАВЛЕНИЯ ЗАБОЛЕВАНИЯМИ. Интернаука, (2-1), 50-51.